Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

CAMBRIDGE, MA / ACCESS Newswire / July 11, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, August 1, 2025 to report i ...

The Allan Labor Government is backing breakthrough research that has potential to save millions of lives worldwide and position Victoria as a global ...

Moderna's COVID-19 vaccine has received full approval from the U.S. Food and Drug Administration (FDA) for use in children ...

Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S.